[go: up one dir, main page]

TNSN04078A1 - Antibodies to cd40 - Google Patents

Antibodies to cd40

Info

Publication number
TNSN04078A1
TNSN04078A1 TNP2004000078A TNSN04078A TNSN04078A1 TN SN04078 A1 TNSN04078 A1 TN SN04078A1 TN P2004000078 A TNP2004000078 A TN P2004000078A TN SN04078 A TNSN04078 A TN SN04078A TN SN04078 A1 TNSN04078 A1 TN SN04078A1
Authority
TN
Tunisia
Prior art keywords
antibodies
relates
human
nucleic acid
acid molecules
Prior art date
Application number
TNP2004000078A
Other languages
English (en)
Inventor
Ronald P Gladue
José Corvalan
Vahe Bedian
Xiao Feng
Xiao-Chi Jia
Original Assignee
Abgenix Inc
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23370387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN04078(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abgenix Inc, Pfizer Prod Inc filed Critical Abgenix Inc
Publication of TNSN04078A1 publication Critical patent/TNSN04078A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA PRESENTE INVENTION CONCERNE LES ANTICORPS ET LES PARTIES ANTIGENE - LIANTES DE TEL ANTICORPS QUI LIENT SPECIFIQUEMENT A CD40; CD40 DE PREFERENCE HUMAIN; ET QUI FONCTIONNENT COMME DES AGONISTES DE CD40. L' INVENTION SE RELIE EGALEMENT AUX ANTICORPS ANTI- CD40 HUMAINS ET AUX PARTIES ANTIGENE - LIANTES DE CELA. L' INVENTION SE RELIE EGALEMENT AUX ANTICORPS QUI SONT LES ANTICORPS OU LES PARTIES DE PROTEINES DE FUSION CHIMERIQUES; BISPECIFIQUES; DERIVATISES; A CHAINE SEULE. L INVENTION SE RELIE EGALEMENT AUX IMMUNOGLOBULINES A CHAINE LOURDE ET LEGERE ISOLEE DERIVEE DES ANTICORPS ANTI -CD40 HUMAINS ET DES MOLECULES D'ACIDE NUCLEIQUE CODANT ET DE TELLES IMMINOGLOBULINES. LA PRESENTE INVENTION SE RELIE EGALEMENT AUX METHODES DE LA FABRICATION DES ANTICORPS ANTI- CD40 HUMAINS; COMPOSITIONS COMPORTANT CES ANTICORPS ET DES METHODES D' EMPLOYER LES ANTICORPS ET LES COMPOSITIONS POUR LE DIAGNOSTIC ET LE TRAITEMENT. L INVENTION FOURNIT EGALEMENT DES METHODES DE THERAPIE DE GENE EN UTILISANT DES MOLECULES D ACIDE NUCLEIQUE CODANT LES MOLECULES LOURDES ET/ OU LEGERES D' IMMUNOGLOBULINE QUI COMPORTENT LES ANTICORPS ANTI- CD40 HUMAINS. L' INVENTION SE RELIE EGALEMENT AUX ANIMAUX DE TRANSFEREMENT GENIQUE (TRANSGENIQUE) COMPORTANT DES MOLECULES D 'ACIDE NUCLEIQUE DE LA PRESENTE INVENTION .
TNP2004000078A 2001-11-09 2004-05-05 Antibodies to cd40 TNSN04078A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34898001P 2001-11-09 2001-11-09
PCT/US2002/036107 WO2003040170A2 (fr) 2001-11-09 2002-11-08 Anticorps anti-cd40

Publications (1)

Publication Number Publication Date
TNSN04078A1 true TNSN04078A1 (fr) 2006-06-01

Family

ID=23370387

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2004000078A TNSN04078A1 (fr) 2001-11-09 2004-05-05 Antibodies to cd40

Country Status (46)

Country Link
US (9) US7288251B2 (fr)
EP (2) EP1476185B1 (fr)
JP (3) JP4616555B2 (fr)
KR (1) KR100830086B1 (fr)
CN (2) CN103450360B (fr)
AP (1) AP1918A (fr)
AR (1) AR039067A1 (fr)
AU (1) AU2002356926B2 (fr)
BR (1) BRPI0214137B8 (fr)
CA (1) CA2466128C (fr)
CL (1) CL2009001779A1 (fr)
CR (2) CR7343A (fr)
CU (1) CU23745A3 (fr)
CY (1) CY1115675T1 (fr)
DK (1) DK1476185T3 (fr)
DO (1) DOP2002000507A (fr)
EA (1) EA011449B1 (fr)
EC (1) ECSP045093A (fr)
EG (1) EG25801A (fr)
ES (1) ES2432968T3 (fr)
GE (1) GEP20074222B (fr)
GT (1) GT200200228A (fr)
HN (1) HN2002000318A (fr)
HR (1) HRP20040525B1 (fr)
HU (1) HU229829B1 (fr)
IL (2) IL161823A0 (fr)
IS (1) IS2940B (fr)
MA (1) MA27139A1 (fr)
ME (1) ME00503B (fr)
MX (1) MXPA04004467A (fr)
MY (1) MY137641A (fr)
NI (1) NI200200128A (fr)
NO (1) NO334339B1 (fr)
NZ (1) NZ533180A (fr)
OA (1) OA12725A (fr)
PA (1) PA8557701A1 (fr)
PE (1) PE20030846A1 (fr)
PL (2) PL214289B1 (fr)
PT (1) PT1476185E (fr)
RS (1) RS52484B (fr)
SI (1) SI1476185T1 (fr)
TN (1) TNSN04078A1 (fr)
TW (2) TWI331040B (fr)
UY (1) UY27537A1 (fr)
WO (1) WO2003040170A2 (fr)
ZA (1) ZA200404207B (fr)

Families Citing this family (267)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244827B2 (en) * 2000-04-12 2007-07-17 Agensys, Inc. Nucleic acid and corresponding protein entitled 24P4C12 useful in treatment and detection of cancer
US6943235B1 (en) * 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
US20050255106A1 (en) * 1999-05-22 2005-11-17 Linda Diehl Induction of anti-tumor ctl immunity through in vivo triggering of 4-1bb and/or cd40
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
AU8886601A (en) 2000-09-07 2002-03-22 John R Schreiber Human antibodies against pseudomonas aeruginosa lps derived from transgenic xenomouse
EP2009027B1 (fr) 2001-04-27 2014-05-21 Kyowa Hakko Kirin Co., Ltd. Anticorps monoclonal anti-CD40
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
CA2466845A1 (fr) 2001-11-21 2003-06-05 Fred Ramsdell Manipulation de taux de cytokine au moyen de produits de gene cd83
US20040185040A1 (en) 2001-11-21 2004-09-23 Celltech R & D Limited Modulating immune responses
PT1531850E (pt) * 2002-06-07 2012-05-07 Zymogenetics Inc Utilização de il-21 e anticorpo monoclonal para tratar cancros sólidos
US7052694B2 (en) * 2002-07-16 2006-05-30 Mayo Foundation For Medical Education And Research Dendritic cell potentiation
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
PL1680140T3 (pl) * 2003-10-16 2011-11-30 Imclone Llc Inhibitory receptora-1 czynnika wzrostu fibroblastów i związane z nim sposoby leczenia
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
ATE476448T1 (de) * 2003-11-04 2010-08-15 Novartis Vaccines & Diagnostic Verwendung von antagonist-anti-cd40-antikörpern zur behandlung von autoimmunkrankheiten und entzündlichen erkrankungen und organtransplantat- abstossung
CA2548015A1 (fr) 2003-12-05 2005-06-23 John R. Schreiber Anticorps humains diriges contre <i>pseudomonas-aeruginosa</i>, derives d'une xenosouris transgenique<sb> </sb>
US20050136055A1 (en) * 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
BRPI0417266B8 (pt) 2003-12-25 2021-05-25 Kyowa Hakko Kirin Co Ltd anticorpo monoclonal, seu uso e composição farmacêutica
BRPI0506768B1 (pt) 2004-01-09 2021-09-21 Pfizer Inc. Anticorpo monoclonal, ou fração de ligação a antígeno do mesmo que se liga especificamente a madcam,composição farmacêutica, vacina, kit de diagnostico, linhagem celular de hibridoma e método para diagnosticar in vitro um distúrbio
JP2007530588A (ja) 2004-03-23 2007-11-01 バイオジェン・アイデック・エムエイ・インコーポレイテッド レセプターカップリング剤およびその治療用途
US20060099203A1 (en) * 2004-11-05 2006-05-11 Pease Larry R B7-DC binding antibody
JP5902367B2 (ja) * 2004-06-30 2016-04-13 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 抗体
CN1997670B (zh) 2004-07-01 2014-04-30 诺和诺德公司 人类抗-kir抗体
US20070286855A1 (en) * 2004-08-03 2007-12-13 Mayo Foundation For Medical Education And Research Improving treatments
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
SI1836225T1 (sl) 2005-01-06 2012-06-29 Novo Nordisk As Kir vezujoäśa sredstva in postopki za njihovo rabo
WO2006075668A1 (fr) * 2005-01-12 2006-07-20 Kirin Beer Kabushiki Kaisha Anticorps igg1 et igg 3 humains stabilisés
EP1866338B1 (fr) * 2005-03-23 2016-09-21 Genmab A/S Anticorps diriges contre cd38 pour le traitement du myelome multiple
GEP20115226B (en) 2005-04-26 2011-06-10 Pfizer P-cadherin antibodies
EP1894012A2 (fr) * 2005-05-18 2008-03-05 Novartis AG Methodes de diagnostic et de traitement des maladies proliferatives mediees par la signalisation cd40
HRP20130852T1 (en) 2005-05-18 2013-10-25 Novartis Ag Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
GB0512225D0 (en) * 2005-06-16 2005-07-27 Univ Sheffield Immunoglobulin molecules
WO2007011968A2 (fr) 2005-07-18 2007-01-25 Seattle Genetics, Inc. Conjugues lieur a base de beta-glucuronide-medicament
SI1933871T1 (sl) 2005-09-07 2013-10-30 Amgen Fremont Inc. Humana monoklonska protitelesa proti aktivin receptorju podobni kinazi-1
WO2007103048A2 (fr) * 2006-03-01 2007-09-13 Regents Of The University Of Colorado Conjugués de protéine agoniste de tlr (flagelline)/agoniste de cd40/ antigène et d'adn et leur utilisation pour induire un renforcement synergique de l'immunité
EP2019857B1 (fr) * 2006-05-03 2016-09-28 The Regents of the University of Colorado, a body corporate Combinaison adjuvante synergique d'anticorps agoniste cd40/interféron de type 1, conjugués contenant une telle combinaison et utilisation en tant qu'agent thérapeutique pour améliorer l'immunite cellulaire
EP2021338A1 (fr) 2006-05-09 2009-02-11 Pfizer Products Inc. Dérivés d'acide cycloalkylaminé et compositions pharmaceutiques à base de ceux-ci
EP1854810A1 (fr) * 2006-05-09 2007-11-14 PanGenetics B.V. Anticorps monoclonal anti CD40 humain déimmunisé et antagoniste dérivé de l'anticorps ch5D12
US9234174B2 (en) * 2006-05-12 2016-01-12 Ospedale San Raffaele S.R.L. Tolerogenic dendritic cells, method for their production and uses therof
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
AU2007332473B2 (en) * 2006-12-14 2012-09-27 Forerunner Pharma Research Co., Ltd. Anti-Claudin-3 monoclonal antibody, and treatment and diagnosis of cancer using the same
EP2064242A1 (fr) * 2007-02-23 2009-06-03 Schering Corporation Anticorps obtenus par génie génétiques dirigés contre l'il-23p19
DK2059534T3 (da) * 2007-02-23 2012-08-06 Merck Sharp & Dohme Gensplejsede anti-il-23p19-antistoffer
DK2176298T3 (en) 2007-05-30 2018-02-12 Xencor Inc Methods and compositions for inhibiting CD32B-expressing cells
EP1997830A1 (fr) * 2007-06-01 2008-12-03 AIMM Therapeutics B.V. Molécules à liaison spécifiques RSV et leur moyen de fabrication
US8039597B2 (en) * 2007-09-07 2011-10-18 Agensys, Inc. Antibodies and related molecules that bind to 24P4C12 proteins
CA2704499C (fr) 2007-11-07 2020-03-10 Genentech, Inc. Procedes et compositions pour evaluer la reactivite d'un lymphome lymphocytaire b a un traitement par anticorps anti-cd40
EP2851374B1 (fr) 2007-12-14 2017-05-03 Bristol-Myers Squibb Company Molécules de liaison au récepteur humain OX40
JO2913B1 (en) * 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
AU2010222929B2 (en) * 2008-07-16 2013-07-25 Baylor Research Institute Antigen presenting cell targeted anti-viral vaccines
EP2328890B1 (fr) 2008-08-06 2012-01-25 Pfizer Inc. Composés 2-hétérocyclylamino pyrazines substituées en position 6 en tant qu'inhibiteurs de chk-1
WO2010024676A1 (fr) * 2008-08-29 2010-03-04 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Administration d’un agoniste de cd40 à un ganglion lymphatique drainant une tumeur d’un sujet
EP2198878A1 (fr) 2008-12-18 2010-06-23 University Of Miami Antagonistes de bombésine en polypeptide
JO3382B1 (ar) * 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
AU2016244220B2 (en) * 2008-12-23 2018-05-17 Amgen Inc. Human CGRP receptor binding proteins
CA2754531A1 (fr) * 2009-03-06 2010-09-30 Seattle Genetics, Inc. Conjugues anticorps-medicament (adc) se liant aux proteines 24p4c12
EP2406286B1 (fr) 2009-03-10 2016-05-18 Baylor Research Institute Anticorps anti-cd40 et utilisations de ceux-ci
DK2406288T3 (en) 2009-03-10 2017-03-27 Baylor Res Inst ANTIGEN PRESENTING CELL-TARGETED VACCINES
JP5836929B2 (ja) 2009-04-18 2015-12-24 ジェネンテック， インコーポレイテッド 抗ｃｄ４０抗体を用いる治療に対するｂ細胞性リンパ腫の応答性を評価するための方法
JP5694921B2 (ja) * 2009-04-20 2015-04-01 協和発酵キリン株式会社 アミノ酸変異が導入されたＩｇＧ２を有する抗体
TW201138843A (en) 2009-12-18 2011-11-16 Colgate Palmolive Co Biguanide preservation of precipitated calcium carbonate
WO2011083391A2 (fr) 2010-01-05 2011-07-14 Pfizer Inc. Biomarqueurs pour une thérapie du cancer par un anti-igf-1r
HUE038788T2 (hu) 2010-03-31 2018-11-28 Boehringer Ingelheim Int Anti-CD40 antitestek
GB201006096D0 (en) * 2010-04-13 2010-05-26 Alligator Bioscience Ab Novel compositions and uses thereof
FR2959994B1 (fr) 2010-05-12 2012-08-24 Lfb Biotechnologies Nouveaux anticorps humanises 12g4 mutes et leurs fragments diriges contre le recepteur humain de l'hormone anti-mullerienne de type ii
JP6105470B2 (ja) 2010-09-09 2017-03-29 ファイザー・インク ４−１ｂｂ結合分子
EP2621951A1 (fr) * 2010-09-29 2013-08-07 Université de Liège Association d'un anticorps monoclonal anti-cd40 agoniste ou d'un ligand du cd40 et d'une bactérie inactivée ou atténuée servant à traiter et/ou à prévenir la mastite
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
US20130273055A1 (en) * 2010-11-16 2013-10-17 Eric Borges Agents and methods for treating diseases that correlate with bcma expression
HUE031197T2 (en) * 2011-01-10 2017-06-28 Ct Atlantic Ltd Combination therapy using tumor-associated antigen-binding antigens
GB201103578D0 (en) 2011-03-02 2011-04-13 Sabrepharm Ltd Dipyridinium derivatives
PT3556774T (pt) * 2011-03-11 2024-02-29 Beth Israel Deaconess Medical Ct Inc Anticorpos anti-cd40 e suas utilizações
EP3536708A1 (fr) 2011-04-19 2019-09-11 Pfizer Inc Combinaisons d'anticorps anti-4-1bb et d'anticorps induisant une cytotoxicité à médiation cellulaire dépendante d'un anticorps (adcc) pour le traitement du cancer
KR20140059168A (ko) 2011-04-21 2014-05-15 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 시신경 척수염 치료용 조성물 및 치료 방법
CA2833743A1 (fr) 2011-04-21 2012-10-26 Bristol-Myers Squibb Company Anticorps polypeptidiques qui antagonisent les cd40
US8778345B2 (en) * 2011-04-29 2014-07-15 Apexigen, Inc. Anti-CD40 antibodies
EP2710042A2 (fr) 2011-05-16 2014-03-26 Fabion Pharmaceuticals, Inc. Protéines de fusion contenant un fab multi-spécifique et procédé d'utilisation
GB201115280D0 (en) * 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
EA027900B1 (ru) 2011-09-22 2017-09-29 Эмджен Инк. Связывающие антиген cd27l белки
JP6184965B2 (ja) 2011-10-28 2017-08-23 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド ポリペプチド構築物およびその使用
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
WO2013091661A2 (fr) * 2011-12-23 2013-06-27 Aarhus Universitet Etiquette d'affinité protéique résistante à la protéolyse
RS62454B1 (sr) 2012-01-31 2021-11-30 Regeneron Pharma Anti-asic1 antitela i njihove upotrebe
WO2013133253A1 (fr) * 2012-03-08 2013-09-12 独立行政法人科学技術振興機構 Agent anticancéreux
AR090263A1 (es) * 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
SG10201603896RA (en) 2012-05-04 2016-07-28 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
EP2861719B1 (fr) 2012-06-18 2021-03-31 Ospedale San Raffaele S.r.l. Compositions et procédés pour faire diminuer une réponse immunitaire
KR102270618B1 (ko) * 2012-10-30 2021-06-30 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
KR102449868B1 (ko) 2013-02-01 2022-10-04 키라 바이오테크 피티와이 리미티드 항-cd83 항체 및 이의 용도
US9708375B2 (en) 2013-03-15 2017-07-18 Amgen Inc. Inhibitory polypeptides specific to WNT inhibitors
AU2014238546C1 (en) 2013-03-18 2019-01-17 Biocerox Products B.V. Humanized anti-CD134 (OX40) antibodies and uses thereof
KR102094022B1 (ko) 2013-04-29 2020-03-30 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 항-cd38 항체 및 감쇠 인터페론 알파-2ｂ와의 융합체
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
AU2014280123B2 (en) 2013-06-14 2019-11-14 Akamis Bio Limited A dosing regime and formulations for type B adenoviruses
RU2655010C2 (ru) 2013-06-17 2018-05-23 Конинклейке Филипс Н.В. Опора субъекта для магнитно-резонансной томографии
GB201311487D0 (en) * 2013-06-27 2013-08-14 Alligator Bioscience Ab Bispecific molecules
US11273204B2 (en) 2013-08-08 2022-03-15 Cytune Pharma IL-15 and IL-15RAPLHA sushi domain based immunocytokines
EP3041863A4 (fr) 2013-09-05 2017-08-16 Amgen Inc. Molécules contenant des fc et présentant des profils de glycoforme prévisibles, uniformes et reproductibles
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
MX373835B (es) 2013-10-25 2020-07-08 Psioxus Therapeutics Ltd Adenovirus oncolíticos armados con genes heterólogos.
GB201322583D0 (en) * 2013-12-19 2014-02-05 Alligator Bioscience Ab Antibodies
BR112016007112A2 (pt) * 2013-12-20 2017-09-19 Hoffmann La Roche Anticorpos que se ligam a angiopoietina 2 (ang-2) humana, usos de um anticorpo que se liga a angiopoietina 2 (ang-2) humana e combinação
JP7037884B2 (ja) 2014-01-13 2022-03-17 ベイラー リサーチ インスティテュート Ｈｐｖ及びｈｐｖ関連疾患に対する新規のワクチン
US10435475B2 (en) 2014-03-07 2019-10-08 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize CD40 to treat IBD
AU2015241038A1 (en) 2014-03-31 2016-10-13 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and OX40 binding agonists
EP3137500A1 (fr) * 2014-04-30 2017-03-08 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Anticorps humanisés dirigés contre cd269 (bcma)
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
US10156562B2 (en) 2014-05-16 2018-12-18 Amgen Inc. Assay for detecting Th1 and Th2 cell populations
GB201413665D0 (en) 2014-07-03 2014-09-17 Transimmune Ag And Yale University Method for obtaining globally activated monocytes
CA2957146A1 (fr) 2014-08-12 2016-02-18 Alligator Bioscience Ab Polytherapies utilisant des anticorps anti-cd40
EP3180357B1 (fr) * 2014-08-14 2019-07-03 F.Hoffmann-La Roche Ag Thérapie de combinaison d'anticorps d'activation cd40 humains et anticorps contre le récepteur humain pd-l1
EP3070102A1 (fr) 2015-03-18 2016-09-21 F. Hoffmann-La Roche AG Thérapie de combinaison a l'aide d'anticorps d'activation du cd40 humain et d'anticorps contre le récepteur humain pd-l1
JP6956631B2 (ja) 2014-09-15 2021-11-02 アムジェン インコーポレイテッド 二重特異性抗ｃｇｒｐ受容体／ｐａｃ１受容体抗原結合タンパク質及びその使用
AU2015336931B2 (en) 2014-10-23 2021-04-29 Kira Biotech Pty Limited CD83 binding proteins and uses thereof
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
UA125637C2 (uk) 2014-10-29 2022-05-11 Тева Фармасьютікалз Острейліа Пті Лтд ЗЛИТИЙ ПОЛІПЕПТИД ІНТЕРФЕРОНУ <font face="Symbol">a2</font>b
EP3212230B1 (fr) 2014-10-29 2021-01-20 Seagen Inc. Dosage et administration des anticorps anti-cd40 non fucosylés
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
HUE053903T2 (hu) 2015-04-13 2021-07-28 Five Prime Therapeutics Inc Kombinációs terápia rák ellen
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
LT3288573T (lt) 2015-04-30 2020-03-25 Psioxus Therapeutics Limited Onkolitinis adenovirusas, koduojantis b7 baltymą
IL302486A (en) 2015-06-24 2023-06-01 Hoffmann La Roche Antibodies against the transnephrine receptor with adapted affinity
EA035268B1 (ru) * 2015-06-29 2020-05-22 Бристол-Маерс Сквибб Компани Антитела к cd40
UY36757A (es) * 2015-06-29 2016-12-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Anticuerpos monoclonales murinos contra cd40 con actividad agonista mejorada
EP3943098A3 (fr) 2015-07-16 2022-05-11 Biokine Therapeutics Ltd. Compositions et procédés pour le traitement du cancer
CN109069621B (zh) 2015-09-04 2022-09-06 普里玛托普医疗股份有限公司 人源化抗-cd40抗体及其用途
EP3356532B1 (fr) * 2015-09-30 2022-01-19 Janssen Biotech, Inc. Anticorps agonistes se liant de manière spécifique au cd40 humain et procédés d'utilisation
KR20250007038A (ko) 2015-10-02 2025-01-13 에프. 호프만-라 로슈 아게 이중특이성 항-인간 cd20/인간 트랜스페린 수용체 항체 및 사용 방법
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
GB2543550A (en) 2015-10-21 2017-04-26 Hox Therapeutics Ltd Peptides
CN108697791B (zh) 2015-11-03 2022-08-23 詹森生物科技公司 特异性结合pd-1的抗体及其用途
EP3964522A1 (fr) * 2015-11-16 2022-03-09 Ubiprotein, Corp. Procédé permettant d'étendre la demi-vie d'une protéine
DE212016000029U1 (de) * 2015-12-07 2017-07-30 Opi Vi - Ip Holdco Llc Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten
CN108697745A (zh) 2015-12-17 2018-10-23 皮斯奥克斯治疗公司 编码抗tcr复合体抗体或片段的b组腺病毒
CN109071655B (zh) * 2016-03-04 2022-08-12 洛克菲勒大学 具有增强的激动剂活性的cd40的抗体
WO2017156349A1 (fr) 2016-03-10 2017-09-14 Cold Genesys, Inc. Méthodes de traitement de tumeurs solides ou lymphatiques par polythérapie
CA3017776A1 (fr) 2016-03-15 2017-09-21 Generon (Shanghai) Corporation Ltd. Proteines de fusion a fab multispecifiques et leur utilisation
EP3432927A4 (fr) 2016-03-24 2019-11-20 Gensun Biopharma Inc. Inhibiteurs trispécifiques pour le traitement du cancer
EP3433278A4 (fr) 2016-03-25 2019-11-06 Seattle Genetics, Inc. Procédé de préparation de lieurs de médicaments pégylés et leurs intermédiaires
RU2018146050A (ru) 2016-05-27 2020-06-29 Эббви Байотерапьютикс Инк. Биспецифические связывающие белки, которые связывают иммуномодулирующий белок и опухолевый антиген
HRP20211882T1 (hr) 2016-05-27 2022-03-04 Abbvie Biotherapeutics Inc. Protutijela protiv cd40 i njihova upotreba
EP3470424B1 (fr) 2016-06-08 2025-04-23 Shanghai Jiao Tong University School of Medicine Séquence de région constante à chaîne lourde d'anticorps pour améliorer l'activité d'anticorps agonistes
EP4371570A3 (fr) 2016-06-08 2024-07-17 Xencor, Inc. Traitement des maladies associées aux igg4 par des anticorps anti-cd19 se réticulant à cd32b
WO2017220988A1 (fr) 2016-06-20 2017-12-28 Kymab Limited Anticorps multispécifiques pour l'immuno-oncologie
MA45672A (fr) 2016-07-14 2019-05-22 Biontech Ag Anticorps multispécifiques dirigés contre cd40 et cd137
CA3030926A1 (fr) 2016-07-19 2018-01-25 Teva Pharmaceuticals Australia Pty Ltd. Polytherapie anti-cd47
CA3033661A1 (fr) 2016-08-12 2018-02-15 Janssen Biotech, Inc. Conception d'anticorps modifies et d'autres molecules contenant un domaine fc presentant des fonctions d'agonisme et d'effecteur ameliorees
SG11201900744SA (en) 2016-08-12 2019-02-27 Janssen Biotech Inc Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
JP7138094B2 (ja) 2016-08-25 2022-09-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト マクロファージ活性化剤と組み合わせた抗ｃｓｆ－１ｒ抗体の間欠投与
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
US12049513B2 (en) 2016-08-29 2024-07-30 Akamis Bio Limited Oncolytic group B adenovirus expressing a stroma-targeted bispecific t-cell engager
KR102019033B1 (ko) 2016-11-11 2019-09-06 다이노나(주) Cd40에 특이적으로 결합하는 항체 및 그의 용도
MX2019007144A (es) 2016-12-19 2019-10-07 Glenmark Pharmaceuticals Sa Nuevos agonistas de tnfr y sus usos.
EP3558360A1 (fr) 2016-12-22 2019-10-30 F. Hoffmann-La Roche AG Traitement de tumeurs par un anticorps anti-csf1r en association avec un anticorps anti-pd-l1 après l'échec d'un traitement anti-pd-l1/pd1
CN109071656B (zh) 2017-01-05 2021-05-18 璟尚生物制药公司 检查点调节物拮抗剂
CA3049842A1 (fr) * 2017-02-02 2018-08-09 Silverback Therapeutics, Inc. Compositions de produit de recombinaison-peptide et leurs methodes d'utilisation
MA47449A (fr) 2017-02-10 2019-12-18 Genmab Bv Variants polypeptidiques et ses utilisations
JP7672196B2 (ja) 2017-03-14 2025-05-07 アムジエン・インコーポレーテツド 細胞培養において産生される抗体の総非フコシル化グリコフォームの調節
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
EP3600443A1 (fr) 2017-03-24 2020-02-05 Seattle Genetics, Inc. Procédé de préparation de lieurs de médicament, à base de glucuronide, et leurs intermédiaires
CA3055433A1 (fr) * 2017-03-29 2018-10-04 Glycotope Gmbh Anticorps anti-cd40 humanises
EP3604385B1 (fr) 2017-03-30 2024-05-01 NOF Corporation Polyéthylène glycol monodispersé hétérobifonctionnel, et conjugué l'utilisant
EP3604384B1 (fr) 2017-03-30 2021-09-08 NOF Corporation Dérivé de polymère hydrophile comportant un coupleur acétal auto-immolable et composite l'utilisant
TWI704158B (zh) * 2017-04-04 2020-09-11 瑞士商赫孚孟拉羅股份公司 能夠特異性結合至cd40及fap之新穎雙特異性抗原結合分子
BR112019021411A2 (pt) 2017-04-13 2020-05-05 Hoffmann La Roche métodos para tratar ou retardar a progressão do câncer e para melhorar a função, usos de um imunoconjugado, de um agonista, de um antagonista, composições, kit e invenção
EP3632932A4 (fr) 2017-06-01 2021-08-18 Jiangsu Hengrui Medicine Co. Ltd. Anticorps anti-cd40, fragment de liaison à l'antigène de celui-ci et utilisation médicale associée
IL270989B2 (en) * 2017-06-01 2024-02-01 Akamis Bio Ltd Oncolytic virus and method
EP3418302A1 (fr) 2017-06-19 2018-12-26 F. Hoffmann-La Roche AG Voies d'administration d'agonistes immunitaires
JP2020521788A (ja) * 2017-06-02 2020-07-27 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 免疫アゴニストの投与経路
TW201920266A (zh) 2017-07-14 2019-06-01 美商輝瑞大藥廠 Madcam 抗體
WO2019036855A1 (fr) 2017-08-21 2019-02-28 Adagene Inc. Molécules anti-cd137 et leur utilisation
CN111225924B (zh) * 2017-09-19 2023-10-10 Mab发现股份有限公司 激动性cd40抗体
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
WO2019093342A1 (fr) 2017-11-08 2019-05-16 協和発酵キリン株式会社 ANTICORPS BISPÉCIFIQUE QUI SE LIE À CD40 ET À EpCAM
EP3732198A1 (fr) 2017-12-27 2020-11-04 Bristol-Myers Squibb Company Anticorps anti-cd40 et leurs utilisations
CN109971723B (zh) * 2017-12-28 2023-07-07 上海细胞治疗研究院 包含CD40抗体与muc1特异性嵌合抗原受体基因的T细胞及其用途
CN109971717B (zh) * 2017-12-28 2023-06-20 上海细胞治疗研究院 共表达cd40抗体与间皮素特异性嵌合抗原受体的t细胞及其用途
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
GB201801614D0 (en) 2018-01-31 2018-03-14 Psioxus Therapeutics Ltd Formulation
WO2019148444A1 (fr) 2018-02-02 2019-08-08 Adagene Inc. Anticorps anti-ctla4 et leurs procédés de fabrication et d'utilisation
WO2019148445A1 (fr) 2018-02-02 2019-08-08 Adagene Inc. Anticorps activables dépendant de la précision/du contexte, et leurs procédés de fabrication et d'utilisation
US12091502B2 (en) 2018-03-13 2024-09-17 Nof Corporation Heterobifunctional compound having monodispersed polyethylene glycol in main chain and side chain
IL276910B2 (en) 2018-03-26 2025-11-01 Amgen Inc Total afucosylated glycoforms of antibodies produced in cell culture
JP2021519790A (ja) 2018-04-02 2021-08-12 アムジェン インコーポレイテッド エレヌマブ組成物及びその使用
WO2019204756A1 (fr) 2018-04-20 2019-10-24 Lyvgen Biopharma Co., Ltd. Anticorps anti-cd40 et leurs utilisations
WO2019217833A1 (fr) * 2018-05-10 2019-11-14 Abvision, Inc. Anticorps monoclonaux qui activent cd40 et leurs utilisations
WO2019232533A1 (fr) * 2018-06-01 2019-12-05 Massachusetts Institute Of Technology Polythérapies à base d'inhibiteurs de hsp90 pour améliorer l'immunogénicité tumorale et leurs procédés d'utilisation
WO2019241730A2 (fr) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Augmentation de l'activité immunitaire par modulation de facteurs de signalisation post-cellulaires
EP3813864A4 (fr) 2018-06-29 2022-07-20 Gensun Biopharma Inc. Antagonistes antitumoraux
MX2021001841A (es) 2018-08-20 2021-05-13 Pfizer Anticuerpos anti-gdf15, composiciones y metodos de uso.
EP3847196A4 (fr) 2018-09-07 2023-01-04 ITabMed (HK) Limited Protéines de liaison à un antigène bispécifiques et leurs utilisations
EP3860653A1 (fr) 2018-10-05 2021-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et systèmes de contrôle des propriétés agonistes de domaines variables d'un anticorps par la lumière
TW202039558A (zh) 2018-11-30 2020-11-01 大陸商江蘇恆瑞醫藥股份有限公司 抗ｃｄ４０抗體、其抗原結合片段及其醫藥用途
KR20210097750A (ko) 2018-11-30 2021-08-09 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Cd40 항체 약학 조성물 및 이의 용도
US20220089758A1 (en) * 2019-01-22 2022-03-24 Revmab Biosciences Usa, Inc. Novel anti-cd40 antibodies
US10570210B1 (en) 2019-03-04 2020-02-25 Beijing Mabworks Biotech Co.Ltd Antibodies binding CD40 and uses thereof
WO2020193718A1 (fr) 2019-03-27 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Protéines recombinantes ayant des propriétés d'activation de cd40
JP7535060B2 (ja) * 2019-04-10 2024-08-15 ナンカイ ユニバーシティ 抗ｃｄ４０抗体およびその使用
EP3962493A2 (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Métodes de modulation de l'activité immunitaire
JP7502281B2 (ja) 2019-05-15 2024-06-18 協和キリン株式会社 Ｃｄ４０とｇｐｃ３に結合するバイスペシフィック抗体
CN113891728A (zh) 2019-05-15 2022-01-04 协和麒麟株式会社 与cd40和fap结合的双特异性抗体
WO2020263312A1 (fr) 2019-06-28 2020-12-30 Gensun Biopharma, Inc. ANTAGONISTE ANTITUMORAL COMPOSÉ D'UN DOMAINE EXTRACELLULAIRE TGFβ1 - RII MUTÉ ET D'UN ÉCHAFAUDAGE D'IMMUNOGLOBULINE
EP4027998A1 (fr) 2019-09-09 2022-07-20 Basilea Pharmaceutica International AG Combinaisons pharmaceutiques comprenant un furazanobenzimidazole et un agoniste de cd40 pour une utilisation dans le traitement de maladies néoplasiques
WO2021060439A1 (fr) 2019-09-26 2021-04-01 日油株式会社 Polyéthylène glycol monodispersé hétérobifonctionnel ayant un lieur peptidique
EP4034556A1 (fr) 2019-09-26 2022-08-03 Amgen Inc. Procédés de production de compositions d'anticorps
CN115052625B (zh) * 2019-12-03 2024-11-01 埃沃特克国际有限责任公司 干扰素相关抗原结合蛋白及其用途
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
IL293640A (en) 2019-12-20 2022-08-01 Amgen Inc CD40 antagonistic mesothelin-targeted multispecific antibody constructs for the treatment of solid tumors
US20210214454A1 (en) * 2020-01-10 2021-07-15 Symphogen A/S Anti-cd40 antibodies and compositions
IL272194A (en) 2020-01-22 2021-07-29 Yeda Res & Dev Multispecific antibodies for use in treating diseases
WO2021215462A1 (fr) 2020-04-23 2021-10-28 ブライトパス・バイオ株式会社 Vaccin peptidique amélioré
EP4559477A3 (fr) 2020-05-13 2025-08-13 Adagene AG Compositions et méthodes de traitement du cancer
US20240279309A1 (en) 2020-05-14 2024-08-22 Molecular Partners Ag Recombinant cd40 binding proteins and their use
KR20230022176A (ko) 2020-05-14 2023-02-14 몰리큘라 파트너스 아게 다중특이적 단백질
EP4157343A2 (fr) 2020-05-26 2023-04-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptides du coronavirus 2 associé au syndrome respiratoire aigu sévère (sars-cov-2) et leurs utilisations à des fins vaccinales
GB202008003D0 (en) 2020-05-28 2020-07-15 Quine Medical Ab Anti-CD40 antibody
WO2021247892A1 (fr) 2020-06-04 2021-12-09 Amgen Inc. Évaluation de procédures de nettoyage d'un procédé de fabrication biothérapeutique
EP4161968A4 (fr) * 2020-06-04 2024-06-26 Selvax Pty Ltd. Anticorps anti-cd40 agonistes
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
EP4200334A4 (fr) * 2020-08-21 2024-08-21 Wuxi Biologics (Shanghai) Co. Ltd. Anticorps agoniste de cd40 et procédé d'utilisation
CA3197930A1 (fr) 2020-10-15 2022-04-21 Amgen Inc. Glycanes relatifs non apparies dans des procedes de production d'anticorps
MX2023005570A (es) 2020-11-12 2023-05-29 Inst Nat Sante Rech Med Anticuerpos conjugados o fusionados al dominio de union del receptor de la proteina de la espicula de sars-cov-2 y usos de los mismos con fines de vacunacion.
EP4267176A1 (fr) 2020-12-23 2023-11-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Vaccin contre chlamydia basé sur le ciblage de l'antigène momp vs4 vers les cellules présentatrices d'antigène
WO2022147481A1 (fr) 2020-12-30 2022-07-07 Ansun Biopharma Inc. Polythérapie d'un virus oncolytique délivrant un antigène étranger et cellule immunitaire modifiée exprimant un récepteur chimérique ciblant l'antigène étranger
KR20230142724A (ko) * 2021-01-08 2023-10-11 브리스톨-마이어스 스큅 컴퍼니 인자 XIa 억제제에 대한 항체 및 항원 결합 펩티드및 그의 용도
KR20230131205A (ko) 2021-01-13 2023-09-12 에프. 호프만-라 로슈 아게 병용 요법
EP4284832A1 (fr) 2021-01-29 2023-12-06 (INSERM) Institut National de la Santé et de la Recherche Médicale Polypeptides antigéniques de chlamydia trachomatis et leurs utilisations à des fins vaccinales
TW202241508A (zh) 2021-01-29 2022-11-01 美商艾歐凡斯生物治療公司 細胞介素相關之腫瘤浸潤性淋巴球組合物及方法
TWI843989B (zh) 2021-02-19 2024-06-01 美商美威高能離子醫療系統公司 用於粒子治療系統之支架
EP4305066A1 (fr) 2021-03-09 2024-01-17 Genmab A/S Agents de liaison multispécifiques dirigés contre cd40 et cd137 en thérapie
WO2022212784A1 (fr) 2021-03-31 2022-10-06 Flagship Pioneering Innovations V, Inc. Polypeptides de thanotransmission et leur utilisation dans le traitement du cancer
EP4352094A1 (fr) 2021-06-07 2024-04-17 Amgen Inc. Utilisation de fucosidase pour contrôler le taux d'afucosylation de protéines glycosylées
EP4365200A4 (fr) * 2021-06-28 2025-04-09 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anticorps anti-cd40, fragment de liaison à l'antigène et son utilisation médicale
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
JP2024525758A (ja) 2021-07-13 2024-07-12 ビオンテック・ソシエタス・エウロパエア がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤
EP4402174A1 (fr) * 2021-09-17 2024-07-24 Novartis AG Méthodes de prévention du rejet de greffe dans une xénogreffe
EP4408537A1 (fr) * 2021-10-01 2024-08-07 MAB Discovery GmbH Anticorps anti-cd40 agonistes en tant qu'agents immunostimulateurs
WO2023059607A1 (fr) 2021-10-05 2023-04-13 Amgen Inc. Liaison de récepteur fc-gamma et teneur en glycane
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody
KR20240103030A (ko) 2021-11-17 2024-07-03 인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰 메디칼르 범용 사르베코바이러스 백신
CA3243419A1 (fr) 2022-01-28 2023-08-03 Iovance Biotherapeutics, Inc. Compositions et procédés de lymphocytes infiltrant les tumeurs associés à la cytokine
KR20250004950A (ko) * 2022-03-07 2025-01-09 아게누스 인코포레이티드 항-ilt2 항체 및 이의 용도
WO2023193239A1 (fr) 2022-04-08 2023-10-12 Peter Peizhi Luo Anticorps anti-cd28 et leurs procédés d'utilisation
US20250249278A1 (en) 2022-04-14 2025-08-07 Institut National de la Santé et de la Recherche Médicale Methods for controlling the tumor cell killing by light
WO2023215725A1 (fr) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions et méthodes pour l'immunothérapie cellulaire
CA3257929A1 (fr) 2022-05-31 2025-04-22 Futuregen Biopharmaceutical (Beijing) Co., Ltd. Anticorps anti-cd40, anticorps bispécifique anti-pd-l1×cd40 et leur utilisation
EP4583999A1 (fr) 2022-09-09 2025-07-16 Bristol-Myers Squibb Company Procédés de séparation d'agent chélateur
CN120035611A (zh) * 2022-09-20 2025-05-23 科锐生物制品私人有限公司 双特异性多肽及其用途
WO2024076969A1 (fr) * 2022-10-04 2024-04-11 Memorial Sloan-Kettering Cancer Center Anticorps anti-cd40 et leurs utilisations
KR20250080855A (ko) 2022-10-05 2025-06-05 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 니파바이러스 감염에 대한 dc 표적 백신
EP4598946A1 (fr) 2022-10-05 2025-08-13 Flagship Pioneering Innovations V, Inc. Molécules d'acide nucléique codant pour des trif et des polypeptides supplémentaires et leur utilisation dans le traitement du cancer
WO2024118836A1 (fr) 2022-11-30 2024-06-06 Iovance Biotherapeutics, Inc. Procédés de production de lymphocytes infiltrant les tumeurs à étape rep raccourcie
AU2023401158A1 (en) 2022-12-01 2025-05-29 BioNTech SE Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
CN115969997B (zh) * 2022-12-19 2024-02-13 华润生物医药有限公司 一种靶向cldn18.2的抗体药物偶联物及其应用
CN116375870B (zh) * 2022-12-30 2023-09-15 优睿赛思(武汉)生物科技有限公司 抗人cd40蛋白的人源化抗体、制备方法及其应用
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024213635A1 (fr) * 2023-04-12 2024-10-17 Evotec International Gmbh Protéines de liaison à l'antigène associées à l'interféron destinées à être utilisées dans le traitement ou la prévention d'une infection par le virus de l'hépatite delta
AU2024256160A1 (en) 2023-04-20 2025-10-02 Amgen Inc. Methods of determining relative unpaired glycan content
WO2025038600A1 (fr) 2023-08-14 2025-02-20 Amgen Inc. Procédés de réduction de couleur jaune
WO2025250159A2 (fr) * 2023-08-24 2025-12-04 The Trustees Of Columbia University In The City Of New York Anticorps mutants d'élimination de glycanes à liaison n et leur utilisation contre des virus de la grippe
WO2025101820A1 (fr) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions et méthodes pour l'immunothérapie cellulaire
CN120424223A (zh) * 2024-02-04 2025-08-05 苏州泽璟生物制药股份有限公司 包含lrrc15抗原结合结构域的多特异性抗体
WO2025245964A1 (fr) * 2024-05-28 2025-12-04 中生康元生物科技(北京)有限公司 Formulation de cellules dendritiques et son procédé de préparation

Family Cites Families (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US439216A (en) * 1890-10-28 Maker
US142358A (en) * 1873-09-02 Improvement in the purification of illuminating-gas
US59427A (en) * 1866-11-06 Improvement in fences
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
WO1986005807A1 (fr) 1985-04-01 1986-10-09 Celltech Limited Lignee cellulaire de myelomes transformee et procede d'expression d'un gene codant un polypeptide eucaryotque employant cette lignee
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) * 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5151510A (en) 1990-04-20 1992-09-29 Applied Biosystems, Inc. Method of synethesizing sulfurized oligonucleotide analogs
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2109602C (fr) 1990-07-10 2002-10-01 Gregory P. Winter Methodes de production de membres de paires de liaison specifiques
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
AU664976B2 (en) 1990-08-29 1995-12-14 Gene Pharming Europe Bv Homologous recombination in mammalian cells
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2405246A1 (fr) 1990-12-03 1992-06-11 Genentech, Inc. Methode d'enrichissement de proteines variantes aux proprietes liantes a lterees
ATE363532T1 (de) 1991-03-01 2007-06-15 Dyax Corp Verfahren zur herstellung bindender miniproteine
US5416367A (en) * 1991-03-06 1995-05-16 Quicklogic Corporation Programmable application specific integrated circuit and logic cell therefor
CA2108147C (fr) 1991-04-10 2009-01-06 Angray Kang Banques de recepteurs heterodimeriques construites a l'aide de phagemides
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
WO1993004169A1 (fr) 1991-08-20 1993-03-04 Genpharm International, Inc. Ciblage de genes dans des cellules animales au moyen de produits de synthese d'adn isogeniques
EP0605522B1 (fr) 1991-09-23 1999-06-23 Medical Research Council Méthodes de production d'anticorps humanisés
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
JPH05242071A (ja) * 1991-11-20 1993-09-21 Mitsubishi Electric Corp 対象システムを制御または決定・推定する方法、およびその装置
ATE295420T1 (de) 1992-02-06 2005-05-15 Chiron Corp Marker für krebs und biosynthetisches bindeprotein dafür
US5874082A (en) 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
WO1994019935A1 (fr) 1993-03-09 1994-09-15 Genzyme Corporation Isolement de constituants d'interet du lait
CA2172376C (fr) 1993-10-01 2008-11-18 William C. Fanslow, Iii Anticorps diriges contre le cd40
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
AU680102B2 (en) * 1993-12-23 1997-07-17 Immunex Corporation Method of preventing or treating disease characterized by neoplastic cells expressing CD40
US5612126A (en) * 1994-01-19 1997-03-18 Burlington Industries, Inc. Stiff fabric and method of forming the stiff fabric
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
JPH0812700A (ja) 1994-07-01 1996-01-16 Sumitomo Electric Ind Ltd マウスｃｄ４０に対するモノクローナル抗体
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
GB9425060D0 (en) * 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
US6046037A (en) 1994-12-30 2000-04-04 Hiatt; Andrew C. Method for producing immunoglobulins containing protection proteins in plants and their use
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
EP0820342B1 (fr) * 1995-04-11 1999-09-01 Robert Bosch Gmbh Procede et dispositif permettant de reduire le taux de polluants, notamment les oxydes d'azote contenus dans des gaz d'echappement
US5861510A (en) 1995-04-20 1999-01-19 Pfizer Inc Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors
AU705616B2 (en) 1995-04-21 1999-05-27 Cell Genesys, Inc. Generation of large genomic DNA deletions
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
EP0823941A4 (fr) 1995-04-28 2001-09-19 Abgenix Inc Anticorps humains derives de xeno-souris immunisees
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5780215A (en) * 1995-07-26 1998-07-14 Konica Corporation Silver halide color photographic light-sensitive material
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
PT780386E (pt) 1995-12-20 2003-02-28 Hoffmann La Roche Inibidores de metaloprotease de matriz
AU719327B2 (en) 1996-03-05 2000-05-04 Astrazeneca Ab 4-anilinoquinazoline derivatives
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
EP0818442A3 (fr) 1996-07-12 1998-12-30 Pfizer Inc. Dérivés cycliques de sulfones comme inhibiteurs de métalloprotéinase et de la production du facteur de nécrose des tumeurs
PT912559E (pt) 1996-07-13 2003-03-31 Glaxo Group Ltd Compostos heterociclicos fundidos como inibidores de proteina tirosina quinase
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
CA2260058A1 (fr) 1996-07-13 1998-01-22 Kathryn Jane Smith Composes heteroaromatiques bicycliques en tant qu'inhibiteurs de la proteine tyrosine kinase
ATE217315T1 (de) 1996-07-18 2002-05-15 Pfizer Matrix metalloprotease-inhibitoren auf basis von phosphinsäuren
EP0922030A1 (fr) 1996-08-23 1999-06-16 Pfizer Inc. Derives de l'acide arylsulfonylamino hydroxamique
US5817690A (en) * 1996-08-27 1998-10-06 American Home Products Corporation 4-aminoethoxy indolone derivatives
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
BR9714266A (pt) 1997-01-06 2000-04-18 Pfizer Derivados de sulfona cìclicos.
IL131042A0 (en) 1997-02-03 2001-01-28 Pfizer Prod Inc Arylsulfonylamino hydroxamic acid derivatives
BR9807824A (pt) 1997-02-07 2000-03-08 Pfizer Derivados de n-hidróxi-beta-sulfonil-propionamida e seu uso como inibidores de metaloproteinases de matriz
WO1998034918A1 (fr) 1997-02-11 1998-08-13 Pfizer Inc. Derives de l'acide arylsulfonylhydroxamique
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1998050356A1 (fr) 1997-05-07 1998-11-12 Sugen, Inc. Derives de 2-indolinone utilises en tant que modulateurs de l'activite de la proteine kinase
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
EP0984692A4 (fr) 1997-05-30 2001-02-21 Merck & Co Inc Nouveaux inhibiteurs d'angiogenese
AU730248B2 (en) 1997-08-08 2001-03-01 Pfizer Products Inc. Aryloxyarylsulfonylamino hydroxamic acid derivatives
ES2289791T3 (es) 1997-08-22 2008-02-01 Astrazeneca Ab Derivados de oxindolilquinazolina como inhibidores de la angiogenesis.
WO1999016755A1 (fr) 1997-09-26 1999-04-08 Merck & Co., Inc. Nouveaux inhibiteurs de l'angiogenese
KR100446363B1 (ko) 1997-11-11 2004-09-01 화이자 프로덕츠 인코포레이티드 항암제로 유용한 티에노피리미딘 및 티에노피리딘 유도체
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
CA2322749A1 (fr) 1998-03-03 1999-09-10 Abgenix, Inc. Molecules fixatrices cd147 utilisees comme agents therapeutiques
JP4462654B2 (ja) 1998-03-26 2010-05-12 ソニー株式会社 映像素材選択装置及び映像素材選択方法
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
AU4009899A (en) 1998-05-23 1999-12-13 Tanox, Inc. Molecules targeting cd40 and tumor cells
EA005032B1 (ru) 1998-05-29 2004-10-28 Сьюджен, Инк. Пирролзамещенные 2-индолиноны (варианты), фармацевтическая композиция (варианты), способ модулирования каталитической активности протеинкиназы, способ лечения или профилактики нарушения в организме, связанного с протеинкиназой
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
WO2000009560A2 (fr) 1998-08-17 2000-02-24 Abgenix, Inc. Production de molecules modifiees avec demi-vie serique prolongee
EP1004578B1 (fr) 1998-11-05 2004-02-25 Pfizer Products Inc. Dérivés d'hydroxamide de l'acide 5-oxo-pyrrolidine-2-carboxylique
EP1051432B1 (fr) 1998-12-08 2007-01-24 Biovation Limited Modification de l'immunogenicite de proteines
CZ303703B6 (cs) 1998-12-23 2013-03-20 Pfizer Inc. Monoklonální protilátka nebo její antigen-vázající fragment, farmaceutická kompozice obsahující tuto protilátku nebo fragment, bunecná linie produkující tuto protilátku nebo fragment, zpusob prípravy této protilátky, izolovaná nukleová kyselina kóduj
WO2000066155A1 (fr) * 1999-04-30 2000-11-09 La Jolla Institute For Allergy And Immunology Methodes pouvant empecher la reactivation d'un virus latent et controler sa replication
US20030118588A1 (en) * 1999-05-22 2003-06-26 Linda Diehl Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
US6946129B1 (en) * 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US6482411B1 (en) * 1999-08-27 2002-11-19 Board Of Regents, The University Of Texas System Methods of reducing bone loss with CD40 ligand
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
GB9927757D0 (en) * 1999-11-25 2000-01-26 Kennedy Rheumatology Inst Treatment of autoimmune diseases
CA2398998C (fr) * 2000-02-01 2014-04-22 Tanox, Inc. Molecules d'activation des apc se liant au cd40
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
WO2001083755A2 (fr) 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Anticorps humains anti-cd40, et leurs procedes de production et d'utilisation
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
ZA200305995B (en) 2001-01-05 2004-08-04 Pfizer Antibodies to insulin-like growth factor I receptor.
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
BRPI0506768B1 (pt) 2004-01-09 2021-09-21 Pfizer Inc. Anticorpo monoclonal, ou fração de ligação a antígeno do mesmo que se liga especificamente a madcam,composição farmacêutica, vacina, kit de diagnostico, linhagem celular de hibridoma e método para diagnosticar in vitro um distúrbio
US20130246300A1 (en) 2012-03-13 2013-09-19 American Express Travel Related Services Company, Inc. Systems and Methods for Tailoring Marketing
US10884952B2 (en) 2016-09-30 2021-01-05 Intel Corporation Enforcing memory operand types using protection keys

Also Published As

Publication number Publication date
ECSP045093A (es) 2004-07-23
AP1918A (en) 2008-11-13
US20070190051A1 (en) 2007-08-16
PT1476185E (pt) 2013-11-05
CL2009001779A1 (es) 2010-02-05
AP2004003034A0 (en) 2004-06-30
JP2010213704A (ja) 2010-09-30
EP2343086A2 (fr) 2011-07-13
US20120225014A1 (en) 2012-09-06
US20090169563A1 (en) 2009-07-02
US7288251B2 (en) 2007-10-30
HK1069122A1 (en) 2005-05-13
JP2013099333A (ja) 2013-05-23
EP1476185B1 (fr) 2013-07-31
HRP20040525A2 (en) 2005-04-30
CN103450360A (zh) 2013-12-18
HUP0402247A2 (hu) 2005-01-28
CN1582165A (zh) 2005-02-16
EA011449B1 (ru) 2009-02-27
US20100098694A1 (en) 2010-04-22
NI200200128A (es) 2010-01-11
KR100830086B1 (ko) 2008-05-20
IL161823A0 (en) 2005-11-20
DOP2002000507A (es) 2003-05-15
NO20042388L (no) 2004-08-09
US20060093600A1 (en) 2006-05-04
RS52484B (sr) 2013-02-28
HU229829B1 (en) 2014-09-29
IS2940B (is) 2016-03-15
CN103450360B (zh) 2016-11-02
US20090130715A1 (en) 2009-05-21
US7618633B2 (en) 2009-11-17
BR0214137A (pt) 2004-09-14
BRPI0214137B1 (pt) 2019-03-19
RS39204A (sr) 2006-12-15
MXPA04004467A (es) 2005-05-16
EP1476185A2 (fr) 2004-11-17
US7338660B2 (en) 2008-03-04
HUP0402247A3 (en) 2012-09-28
MA27139A1 (fr) 2005-01-03
CA2466128C (fr) 2013-10-29
GT200200228A (es) 2008-09-26
PA8557701A1 (es) 2003-12-19
UY27537A1 (es) 2003-02-28
GEP20074222B (en) 2007-10-25
CR7343A (es) 2004-10-28
EP2343086A3 (fr) 2012-02-22
EP1476185A4 (fr) 2007-04-04
AU2002356926C1 (en) 2003-05-19
US7563442B2 (en) 2009-07-21
PL214289B1 (pl) 2013-07-31
SI1476185T1 (sl) 2013-12-31
KR20050063749A (ko) 2005-06-28
US20030211100A1 (en) 2003-11-13
US20130024956A1 (en) 2013-01-24
WO2003040170A3 (fr) 2003-10-09
US8388971B2 (en) 2013-03-05
ME00503B (me) 2011-10-10
JP2005508176A (ja) 2005-03-31
TW201034686A (en) 2010-10-01
CN1582165B (zh) 2013-05-29
AU2002356926A2 (en) 2003-05-19
JP4616555B2 (ja) 2011-01-19
NZ533180A (en) 2008-03-28
EA200400654A1 (ru) 2004-12-30
NO334339B1 (no) 2014-02-10
OA12725A (en) 2006-06-28
CY1115675T1 (el) 2017-01-25
AR039067A1 (es) 2005-02-09
TWI331040B (en) 2010-10-01
CA2466128A1 (fr) 2003-05-15
TWI338579B (en) 2011-03-11
JP5547532B2 (ja) 2014-07-16
BRPI0214137B8 (pt) 2021-05-25
ZA200404207B (en) 2005-08-31
PL392809A1 (pl) 2011-03-14
US20160152713A1 (en) 2016-06-02
PL214634B1 (pl) 2013-08-30
CU23745A3 (es) 2012-01-31
EG25801A (en) 2012-08-08
JP5848232B2 (ja) 2016-01-27
IS7253A (is) 2004-05-06
HRP20040525B1 (hr) 2017-06-02
DK1476185T3 (da) 2013-10-14
CR10878A (es) 2011-01-12
WO2003040170A2 (fr) 2003-05-15
IL161823A (en) 2014-02-27
WO2003040170A9 (fr) 2004-06-10
TW200306204A (en) 2003-11-16
HN2002000318A (es) 2003-03-10
PL370514A1 (en) 2005-05-30
PE20030846A1 (es) 2003-10-11
US7626012B2 (en) 2009-12-01
MY137641A (en) 2009-02-27
ES2432968T3 (es) 2013-12-05
AU2002356926B2 (en) 2007-01-04

Similar Documents

Publication Publication Date Title
TNSN04078A1 (fr) Antibodies to cd40
MY140862A (en) ANTIBODIES TO MAdCAM
AP2072A (en) Antibodies to insulin-like growth factor I receptor
AU2003220525A8 (en) Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same
MX346194B (es) Anticuerpos anti-m-csf.
TNSN07394A1 (en) Antibodies to myostatin
EP2447283A3 (fr) Anticorps monoclonaux humains dirigés contre la kinase-1 du type du récepteur d&#39;activine (ALK-1)
WO2008019290A3 (fr) Anticorps anti-erbb2
LU92041I2 (fr) Anticorps monoclonal humain qui se lie au CD20 humain, qui est capable d&#39;induite une cytotoxité dépendente du complément des cellules exprimant CD2, en présence du complément et qui comprend les régions CDR de la chaîne légère et de la chaîne lourde selon EP1558648B1 revendication 1, paragraphes (i),(ii)(a) et (iii)(SEQ ID nos 16,17,18,13,14 et 15) en particulier un anticorps comprenant les séquen ces de la région variable de la chaîne légère et de la chaîne lourde selon EP1558648B1 revendication 4 (SEQ ID nos 4 et 2), en particulier ofatumumab
MA29374B1 (fr) Anticorps anti-ccr5 et leurs utilisations
MA48241A1 (fr) Anticorps dirigés contre madcam
TNSN02089A1 (fr) Anticorps a cd40
MA48870B1 (fr) Anticorps anti-sortiline et leurs méthodes d&#39;utilisation